Solid Biosciences Inc Dossier
Qualitative Analysis
Business overview
Solid Biosciences Inc. (NASDAQ: SLDB) is a clinical-stage biotechnology company dedicated to developing transformative genetic medicines for neuromuscular and cardiac diseases. The company's pipeline is anchored by its lead gene transfer candidate, SGT-003, a next-generation microdystrophin gene therapy utilizing a novel, muscle-tropic capsid (POLARIS-101™) designed to treat Duchenne muscular dystrophy (DMD). Solid's broader pipeline includes SGT-212 for Friedreich's ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), and several preclinical cardiac programs. The company operates in a single segment focused on gene therapy development.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing SGT-003, a next-generation micro-dystrophin gene therapy candidate utilizing the muscle-tropic POLARIS-101™ capsid, through the Phase 1/2 INSPIRE DUCHENNE and Phase 3 IMPACT DUCHENNE clinical trials.
Expected impact: Establish SGT-003 as a highly differentiated, potent, and safe gene therapy alternative for Duchenne muscular dystrophy.
Broadening the commercial and scientific reach of the proprietary POLARIS-101™ (formerly AAV-SLB101) capsid technology through non-exclusive licensing agreements and co-marketing partnerships.
Expected impact: Generates non-dilutive revenue, validates the platform's utility across the gene therapy industry, and establishes industry-wide standards for muscle-targeted delivery.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To create a diversified genetic medicines company combining Solid's Duchenne muscular dystrophy expertise with AavantiBio's cardiac programs (including Friedreich's ataxia candidate SGT-212) and next-generation capsid platform.
Financial impact: Brought in additional pipeline assets and led to a corporate restructuring, including the appointment of Bo Cumbo as President and CEO.
Strategic Partnerships
Grants Andelyn a non-exclusive worldwide license to offer Solid's proprietary POLARIS-101™ (AAV-SLB101) capsid to its gene therapy clients, optimizing manufacturing processes using Andelyn's AAV Curator® Platform.
Terms: Specific financial terms were not disclosed.
Designed to increase visibility and access to Solid's POLARIS-101™ capsid technology and NanoMosaic's Tessie™ platform for multi-omic capsid and transgene analytics, helping developers connect advanced delivery with advanced measurement.
Terms: Specific financial terms were not disclosed.